000147817 001__ 147817
000147817 005__ 20250109150035.0
000147817 0247_ $$2doi$$a10.1002/cncr.26433
000147817 0248_ $$2sideral$$a129731
000147817 037__ $$aART-2012-129731
000147817 041__ $$aeng
000147817 100__ $$aLin, Pei
000147817 245__ $$aPrognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma
000147817 260__ $$c2012
000147817 5203_ $$aBACKGROUND: B-cell lymphoma, Unclassifiable with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma, for convenience referred to here as unclassifiable B-cell lymphoma, is a category in the 2008 World Health Organization system used for a group of histologically aggressive neoplasms that are difficult to classify definitively. Currently, there is no established standard therapy for these neoplasms.
METHODS: The authors assessed MYC status and correlated it with treatment response and outcome in a group of 52 patients with unclassifiable B-cell lymphoma treated with either a standard DLBCL regimen (R-CHOP [rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone-related therapy]) or more intensive regimens, such as R-hyper-CVAD (rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine). The regimens were selected by the treating clinicians based on the overall clinical and pathological findings.
RESULTS: Thirty (58%) unclassifiable B-cell lymphomas had MYC abnormalities (MYC+) including 27 with rearrangement, 2 with amplification, and 1 with both. The MYC+ and MYC− groups were similar in their age distribution and International Prognostic Index scores. Progression-free survival of patients with MYC+ unclassifiable B-cell lymphoma treated initially with R-CHOP was significantly worse than patients treated with R-hyper-CVAD (P = .0358). In contrast, for the MYC− unclassifiable B-cell lymphoma group, some patients responded to R-CHOP, and others were refractory to R-hyper-CVAD.
CONCLUSIONS: MYC aberrations are common in unclassifiable B-cell lymphoma. The presence of MYC aberrations identifies a patient subset that requires more aggressive therapy than R-CHOP. In contrast, MYC− unclassifiable B-cell lymphoma patients responded variably to either R-CHOP or aggressive therapy, and the latter showed no survival advantage.
000147817 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000147817 590__ $$a5.201$$b2012
000147817 591__ $$aONCOLOGY$$b32 / 197 = 0.162$$c2012$$dQ1$$eT1
000147817 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000147817 700__ $$aDickason, Timothy J.
000147817 700__ $$aFayad, Luis E.
000147817 700__ $$aLennon, Patrick A.
000147817 700__ $$aHu, Peter
000147817 700__ $$0(orcid)0000-0003-2078-8205$$aGarcía, Mar
000147817 700__ $$aRoutbort, Mark J.
000147817 700__ $$aMiranda, Roberto
000147817 700__ $$aWang, Xumei
000147817 700__ $$aQiao, Wei
000147817 700__ $$aMedeiros, L. Jeffrey
000147817 773__ $$g118, 6 (2012), 1566-1573$$pCancer$$tCANCER$$x0008-543X
000147817 8564_ $$s1448955$$uhttps://zaguan.unizar.es/record/147817/files/texto_completo.pdf$$yVersión publicada
000147817 8564_ $$s2471578$$uhttps://zaguan.unizar.es/record/147817/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000147817 909CO $$ooai:zaguan.unizar.es:147817$$particulos$$pdriver
000147817 951__ $$a2025-01-09-14:59:01
000147817 980__ $$aARTICLE